Opus Genetics, Inc. (IRD) — Stock Score Summary

Opus Genetics, Inc. (IRD) has a MoatMap StockRank of 44/100 based on Quality (17/100), Value (45/100), and Momentum (68/100) factor scores. The current signal is HOLD. Opus Genetics is an early-stage gene therapy company with a very low quality score of 18. It lacks commercialized products, pricing power, and predictable cash flows, making it highly speculative and unsuitable for our quality-focused mandate.

Opus Genetics is a gene therapy company focused on developing therapies for inherited retinal diseases (IRDs), addressing unmet medical needs in conditions like Leber Congenital Amaurosis. Its competitive moat is based on pioneering scientific research, a targeted pipeline addressing specific genetic mutations, and potential first-in-class treatments for severe and rare ophthalmic conditions. Opus Genetics is a highly specialized biotech firm, aiming to be a leader in the nascent field of gene therapy for retinal degenerations.

Key Financial Metrics

Price$4.08
Market Cap$342M
P/E (Forward)-6.68
Price/Book-7.23
Return on Equity-7594.6%
Return on Invested Capital-113.3%
Gross Margin-157.1%
Operating Margin-665.9%
Revenue Growth-50.6%

Opus Genetics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Opus Genetics, Inc.’s (IRD) StockRank?
MoatMap’s StockRank for Opus Genetics, Inc. (IRD) is 44/100, with a Hold signal. It is a composite of Quality (17), Value (45), and Momentum (68) factor ranks across MoatMap’s 19,000+ stock universe.
Does Opus Genetics, Inc. have an economic moat?
Opus Genetics, Inc. (IRD) has a Quality factor score of 17/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Opus Genetics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Opus Genetics, Inc. (IRD) is Hold, based on a StockRank of 44/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Opus Genetics, Inc. in?
Opus Genetics, Inc. (IRD) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksIRD deep dive reportAI ChampionsHow we score stocksSense-check another stock